Furmonertinib covalently inhibits mutant EGFR kinase (e.g., T790M/activating), blocking EGFR phosphorylation and downstream MAPK/PI3K–AKT signaling, leading to growth arrest and apoptosis of EGFR‑mutant tumor cells.